Humanigen Inc (HGENQ)

[DonDonDonDon]

According to The Chest Journal publication, the 25% of patients in the lenzilumab's LIVE-AIR trial that had the lowest CRP levels had a hazard ratio of 8.33 in the treatment arm. Those were the 119 patients with a CRP level below 41mg/L. A hazard ratio of 8.33 means that those patients had 8.33-fold efficacy or 733% efficacy. 733% efficacy is absolutely insane. The obvious conclusion is that all patients who become hospitalized with Covid should be given lenzilumab the moment they are admitted into the hospital. The US FDA didn't have the CRP data when they decided on lenz's EUA. They have that data now. Good things are going to come from this month's type B meeting with the US FDA.

https://journal.chestnet.org/article/S0012-3692(21)03654-0/fulltext